EntryPoint Capital’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
Other funds holding GILD
EntryPoint Capital's GILD Position: Q2 2026 in Review
EntryPoint Capital increased its Gilead Sciences (GILD) stake by 528% in Q2 2026, buying an estimated $1.51M and bringing the position to 13,595 shares worth $1.72M. The position accounts for 0.42% of the portfolio, ranked #9.
EntryPoint Capital first reported a position in GILD in Q4 2023 and has held it in 5 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- EntryPoint Capital held 13,595 shares of Gilead Sciences worth $1.72M as of Q2 2026.
- EntryPoint Capital bought 11,430 Gilead Sciences shares in Q2 2026, an estimated $1.51M.
- Gilead Sciences made up 0.42% of EntryPoint Capital's portfolio in Q2 2026, its #9 holding.
- EntryPoint Capital first reported a position in Gilead Sciences in Q4 2023 and has held it in 5 quarters since.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.